Factors affecting survival and prognosis in extensive stage small cell lung cancer DOI Creative Commons
Mert Erciyestepe, Ömer Burak Ekinci, Haldun Doğan

и другие.

BMC Pulmonary Medicine, Год журнала: 2025, Номер 25(1)

Опубликована: Апрель 8, 2025

Although chemotherapy significantly improves the quality of life and prolongs survival in patients with extensive-stage small cell lung cancer (ES-SCLC), relapse is almost inevitable, only 5% surviving two years after initial diagnosis. Prophylactic cranial irradiation (PCI) considered for who achieve a complete response, as it has been shown to improve rates this population. Recent studies have also demonstrated that adding PD-L1 inhibitors, such atezolizumab or durvalumab, first-line treatment enhances compared alone. Our study was conducted retrospectively at single center, including 280 ES-SCLC began therapy our institution between July 2009 February 2023. Patients underwent thoracic residual radiotherapy (p< 0.001) PCI showed statistically significant improvements OS. In group, median overall (OS) receiving cisplatin+etoposide 12.0 months (10.71 - 13.28), while those treated carboplatin+etoposide had OS 7.0 (4.58 9.41). For carboplatin+etoposide+atezolizumab, 35.0 (21.32 48.67), difference observed 0.001). study, 7 received ≤ 4 cycles first line 14 > treatment. After treatment, proportion progression-free (PFS) 0 3 21%, 6 24%. PFS notably worse bone, liver, brain metastases diagnosis Multivariate analysis revealed carboplatin+etoposide+atezolizumab second reduced risk both progression death, death. conclusion, remains one most challenging malignancies, characterized by poor short intervals. Multiple factors influence PFS, some which are intrinsic patient disease contrast, others, modalities, number cycles, application radiotherapy, can be modified clinicians.

Язык: Английский

Factors affecting survival and prognosis in extensive stage small cell lung cancer DOI Creative Commons
Mert Erciyestepe, Ömer Burak Ekinci, Haldun Doğan

и другие.

BMC Pulmonary Medicine, Год журнала: 2025, Номер 25(1)

Опубликована: Апрель 8, 2025

Although chemotherapy significantly improves the quality of life and prolongs survival in patients with extensive-stage small cell lung cancer (ES-SCLC), relapse is almost inevitable, only 5% surviving two years after initial diagnosis. Prophylactic cranial irradiation (PCI) considered for who achieve a complete response, as it has been shown to improve rates this population. Recent studies have also demonstrated that adding PD-L1 inhibitors, such atezolizumab or durvalumab, first-line treatment enhances compared alone. Our study was conducted retrospectively at single center, including 280 ES-SCLC began therapy our institution between July 2009 February 2023. Patients underwent thoracic residual radiotherapy (p< 0.001) PCI showed statistically significant improvements OS. In group, median overall (OS) receiving cisplatin+etoposide 12.0 months (10.71 - 13.28), while those treated carboplatin+etoposide had OS 7.0 (4.58 9.41). For carboplatin+etoposide+atezolizumab, 35.0 (21.32 48.67), difference observed 0.001). study, 7 received ≤ 4 cycles first line 14 > treatment. After treatment, proportion progression-free (PFS) 0 3 21%, 6 24%. PFS notably worse bone, liver, brain metastases diagnosis Multivariate analysis revealed carboplatin+etoposide+atezolizumab second reduced risk both progression death, death. conclusion, remains one most challenging malignancies, characterized by poor short intervals. Multiple factors influence PFS, some which are intrinsic patient disease contrast, others, modalities, number cycles, application radiotherapy, can be modified clinicians.

Язык: Английский

Процитировано

0